Jack O'Brien

Most recent articles by Jack O'Brien

MM+M’s Marc Iskowitz honored for third consecutive time at Neal Awards

Jack O'Brien

April 26, 2024

2:02 pm

Iskowitz has won Best Range of Work by a Single Author for three years running.

AbbVie and Gilead post solid Q1 earnings, update full year outlooks

Jack O'Brien

April 26, 2024

11:01 am

AbbVie’s net revenue from its immunology portfolio dropped nearly 4% to $5.3 billion due to increased Humira biosimilar competition.

Rx Rundown: Xaira Therapeutics, Ipsen, Sanofi and more

Jack O'Brien

April 26, 2024

7:00 am

Check out this week’s medical marketing news, dealmaking and industry chatter.

Five things for pharma marketers to know for Friday morning

Jack O'Brien

April 26, 2024

5:00 am

Rinvoq tops Dupixent in head-to-head study; Bird flu outbreak in cows is widespread; Regeneron teams with Mammoth on gene editing therapies.

Former <i>Dance Moms</i> star takes the lead in Ad Council’s mental health campaign

Former Dance Moms star takes the lead in Ad Council’s mental health campaign

Jack O'Brien

April 25, 2024

4:33 pm

Capture the Convo marks former Dance Moms star Nia Sioux’s directorial debut and features her friends sharing how to have mental health conversations that can be both necessary and difficult.

Big Pharma Q1 earnings roundup: AstraZeneca, BMS, Merck, Sanofi

Jack O'Brien

April 25, 2024

11:56 am

A group of prominent pharma companies unveiled their respective earnings Thursday morning, with some soaring and others reeling.

The Escalator: Xaira Therapeutics, Haleon, The Bloc and more

Jack O'Brien

April 25, 2024

7:30 am

See which leaders are on the move across the pharma, biotech and medical marketing industries.

Five things for pharma marketers to know for Thursday morning

Jack O'Brien

April 25, 2024

5:00 am

DOJ launches investigation into McKinsey’s past work for opioid manufacturers; Spending on GLP-1 drugs balloons; UnitedHealth Group is shutting down Optum’s virtual care business.

Haleon names Dawn Allen as CFO, succeeding outgoing Tobias Hestler

Jack O'Brien

April 24, 2024

2:49 pm

Hestler will leave his post on November 1 but will continue with Haleon until the end of the year to ensure an orderly leadership transition.

Biogen beats analyst estimates with Leqembi boost, Roche sales fall in Q1

Jack O'Brien

April 24, 2024

12:31 pm

In addition to Leqembi, Biogen’s postpartum depression drug Zurzuvae generated $12 million in quarterly revenues, topping the $2 million it brought in last quarter.